Hospital Clínic de Barcelona
- Country
- 🇪🇸Spain
- Ownership
- Private
- Established
- 1906-01-01
- Employees
- 1K
- Market Cap
- -
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
News
TAR-210 Shows Promise in FGFR-Altered Non-Muscle Invasive Bladder Cancer
A phase 1 study evaluates TAR-210, an intravesical formulation of erdafitinib, for high- and intermediate-risk non-muscle invasive bladder cancer (NMIBC).
TAR-210 Shows Promise in FGFR-Altered Non-Muscle Invasive Bladder Cancer
TAR-210, an intravesical delivery system for erdafitinib, demonstrates early clinical activity in patients with FGFR-altered high- and intermediate-risk NMIBC.
CAR-T Cell Therapy Shows Promise Despite Significant Safety Challenges in Clinical Trials
CAR-T cell therapy demonstrates remarkable efficacy in treating hematological malignancies, with CD19-targeted therapies achieving 67% complete remission rates in acute lymphoblastic leukemia and 82% objective response rates in non-Hodgkin lymphoma patients.